The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The rule is significantly more restrictive than approaches used to mitigate risks during past Ebola outbreaks and creates a standing administrative authority that may allow the CDC to quickly issue suspensions or place strict restrictions on entry of any noncitizen, including lawful permanent residents, under situations it deems to be high-risk public health emergencies in the future.
As of early March, a majority of the public (59%) is worried about affording prescription drugs for themselves and their families, the largest share since KFF first polled this question in 2018.
In addition to ongoing litigation, last September the Trump administration FDA, after requests from anti-abortion organizations and state attorneys general, initiated an internal review of mifepristone’s safety. This adds uncertainty as the agency could revise dispensing rules independently of the courts. With the FDA commissioner’s resignation this week and no permanent leader in place, the timeline for completing the review remains unclear.
The outbreak is also a kind of test case for how well the U.S. is positioned to respond to global disease threats under the Trump administration. Since early last year, the administration has pulled back U.S. engagement on global health, which has included completing a withdrawal from membership in the World Health Organization (WHO)...
The latest KFF Health Tracking Poll shows that Secretary Kennedy continues to be popular among President Trump’s MAGA base and somewhat popular among supporters of his Make America Healthy Again (MAHA) movement, but his appeal beyond those two groups is limited.
Extending the short-term GLP-1 Bridge program is good news for eligible Medicare beneficiaries because it provides the certainty of obesity drug coverage at a $50 copay for a longer duration, but federal spending will also rise by some unknown amount since CMS hasn’t disclosed the projected cost.
Despite for calls from Republican leaders and anti-abortion organizations for the FDA to act quickly, the Louisiana district court has given the FDA until October 7, 2026, one month before the midterms, to file a report with the status of its review and any updated timeframe for completion. In the meantime, clinicians may continue to mail mifepristone to pregnant patients seeking abortions regardless of where they live.
The Trump administration this week backed off a key element of its Medicare Advantage rate proposal, resulting in billions of dollars in additional payments to private insurers.
Certain insurers must now publicly report specific prior authorization metrics, but the new data offer limited insight, providing no information on what types of services are being approved and denied or why as well as no data on prescription drugs.
On the 16th anniversary of the Affordable Care Act’s (ACA) passage, most of the public (61%) view the law favorably, though opinions and debates remain as partisan as ever....As voters continue to grapple with the affordability of coverage and care, the partisan legacy of the ACA will almost certainly figure into debates about health care costs this fall.
© 2026 KFF
